Home > Insider Trading > Filing (0000315066-12-003704)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1446847	Ironwood Pharmaceuticals Inc	IRWD	Pharmaceutical Preparations (2834)	043404176

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
315066	Fmr Llc	82 Devonshire Street Boston MA 02109		No	No	Yes	Yes
318989	Ltd Fil	P.o. Box H.m. 670 Hamilton D0 00000		No	No	Yes	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2012-07-03	9,392	$13.96	2,394,871	No	4	S	Indirect	Footnote
Class A Common Stock	Disposition	2012-07-05	16,960	$14.00	2,377,911	No	4	S	Indirect	Footnote
Class A Common Stock	Disposition	2012-07-06	18,065	$13.90	2,359,846	No	4	S	Indirect	Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Footnote
No	4	S	Indirect	Footnote
No	4	S	Indirect	Footnote

Footnotes

Column 5 Amount of Securities Beneficially Owned Following Reported Transaction is held by Impresa Fund II LLC (1,049,144 Class A Common Stock), Impresa Fund III Limited Partnership (74,798 Class A Common Stock), Fidelity BioSciences Corp. (10,971 Class A Common Stock) and FIL Limited (1,224,933 Class A Common Stock). Column 5 does not include shares beneficially owned by Fidelity Management & Research Company as a result of acting as investment adviser to various investment companies as disclosed in Remark 1 below.
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.95 to $14.11. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.88 to $13.94. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.